ReviewMolecular biology reports2026
Modeling Moyamoya disease using patient-derived induced pluripotent stem cells and organoids.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The underlying mechanisms of Moyamoya disease (MMD), a rare, progressive cerebrovascular disorder marked by distal internal carotid artery stenosis or occlusion and the formation of fragile collaterals, remain poorly understood, in part because conventional models fail to capture the genetic, vascular, and neurovascular complexity of human MMD. Driven by recent advances in disease modeling, MMD research has moved beyond early endothelial progenitor cell studies toward patient-derived induced pluripotent stem cell (iPSC)-based platforms. Here, we summarize the generation and validation of MMD-specific iPSCs and their differentiation into endothelial cells (ECs), vascular smooth muscle cells (VSMCs), and related vascular lineages, and we discuss how two-dimensional (2D) iPSC-based models have provided insights into impaired angiogenesis, endothelial dysfunction, abnormal VSMC behavior, and disrupted vascular cell interactions. We then highlight the emerging use of three-dimensional vascular and neurovascular organoids, which reproduce cellular heterogeneity, vessel-like organization, and neurovascular unit interactions more closely than conventional 2D cultures. These models may provide a more integrated platform for investigating the complex vascular pathophysiology of MMD. Finally, we discuss future directions for MMD modeling, including the integration of multi-omics profiling and CRISPR-mediated genome editing with patient-derived iPSC and organoid platforms. These approaches may help clarify genotype-phenotype relationships, RNF213-dependent and RNF213-independent mechanisms, and disease-relevant molecular pathways. With further standardization and validation, iPSC- and organoid-based models could support mechanistic studies, therapeutic screening, and personalized disease modeling. Our review underscores the emerging role of patient-derived stem cell and organoid technologies in advancing MMD research and in informing future translational efforts.
Indexed as
Identifiers
42886421What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.